Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamila Wojas-Krawczyk

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
International Journal of Molecular Sciences|March 25, 2022
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?Natalia Krzyżanowska, Kamila Wojas-Krawczyk, Janusz Milanowski, et al.
Translational Lung Cancer Research|January 20, 2025
Emerging insights into <i>STK11</i>, <i>KEAP1</i> and <i>KRAS</i> mutations: implications for immunotherapy in patients with advanced non-small cell lung cancerMagdalena Knetki-Wróblewska, Kamila Wojas-Krawczyk, Paweł Krawczyk, et al.
Cells|October 27, 2022
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?Natalia Krzyżanowska, Paweł Krawczyk, Kamila Wojas-Krawczyk, et al.
International Journal of Molecular Sciences|April 21, 2019
Beyond PD-L1 Markers for Lung Cancer ImmunotherapyKamila Wojas-Krawczyk, Ewa Kalinka, Anna Grenda, et al.
Journal of Clinical Medicine|March 25, 2022
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and <i>RET</i> Fusion-Which Path Should We Follow? Case Reports and Literature ReviewMagdalena Knetki-Wróblewska, Kamila Wojas-Krawczyk, Dariusz M Kowalski, et al.
Expert Review of Anticancer Therapy|September 11, 2018
Preventing central nervous system metastases in non-small cell lung cancerPaweł Krawczyk, Renata Duchnowska, Marcin Nicoś, et al.
Pulmonary Pharmacology & Therapeutics|January 18, 2017
Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary diseaseJustyna Emeryk-Maksymiuk, Andrzej Emeryk, Paweł Krawczyk, et al.
Cancers|July 27, 2022
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown PrimaryPaweł Krawczyk, Jacek Jassem, Kamila Wojas-Krawczyk, et al.
Folia Histochemica Et Cytobiologica|April 26, 2012
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot studyPaweł Krawczyk, Kamila Wojas-Krawczyk, Radosław Mlak, et al.
Cancers|August 23, 2020
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature ReviewMarta Dudzińska, Michał Szczyrek, Kamila Wojas-Krawczyk, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
International Journal of Molecular Sciences|March 25, 2022
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?Natalia Krzyżanowska, Kamila Wojas-Krawczyk, Janusz Milanowski, et al.
Translational Lung Cancer Research|January 20, 2025
Emerging insights into <i>STK11</i>, <i>KEAP1</i> and <i>KRAS</i> mutations: implications for immunotherapy in patients with advanced non-small cell lung cancerMagdalena Knetki-Wróblewska, Kamila Wojas-Krawczyk, Paweł Krawczyk, et al.
Cells|October 27, 2022
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?Natalia Krzyżanowska, Paweł Krawczyk, Kamila Wojas-Krawczyk, et al.
International Journal of Molecular Sciences|April 21, 2019
Beyond PD-L1 Markers for Lung Cancer ImmunotherapyKamila Wojas-Krawczyk, Ewa Kalinka, Anna Grenda, et al.
Journal of Clinical Medicine|March 25, 2022
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and <i>RET</i> Fusion-Which Path Should We Follow? Case Reports and Literature ReviewMagdalena Knetki-Wróblewska, Kamila Wojas-Krawczyk, Dariusz M Kowalski, et al.
Expert Review of Anticancer Therapy|September 11, 2018
Preventing central nervous system metastases in non-small cell lung cancerPaweł Krawczyk, Renata Duchnowska, Marcin Nicoś, et al.
Pulmonary Pharmacology & Therapeutics|January 18, 2017
Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary diseaseJustyna Emeryk-Maksymiuk, Andrzej Emeryk, Paweł Krawczyk, et al.
Cancers|July 27, 2022
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown PrimaryPaweł Krawczyk, Jacek Jassem, Kamila Wojas-Krawczyk, et al.
Folia Histochemica Et Cytobiologica|April 26, 2012
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot studyPaweł Krawczyk, Kamila Wojas-Krawczyk, Radosław Mlak, et al.
Cancers|August 23, 2020
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature ReviewMarta Dudzińska, Michał Szczyrek, Kamila Wojas-Krawczyk, et al.
Pageof 7